Glutarate was shown to act as competitive inhibitor of α-ketoglutarate-dependent dioxygenases, to modulate mitochondrial function by controlling pyruvate dehydrogenase complex via disruption of lipoylation, and to enhance the cytotoxicity of CD8 + T cells against target cells, consequently reducing tumor growth. This evidence concerns the gene CD8A and neoplasm.